Kianoosh Kaveh, DO
Nephrology · Port Charlotte, FLNPI 1174524219
Payments from drug & device makers
Across 202 payments — averaging $5374.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$416K
- Eli Lilly$304K
- GSK$191K
- Gilead$65K
- Kadmon Corporation LLC$52K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$22K
- plus $36K from 26 others
Across 2 payments — averaging $41,731 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$83K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 24 | $415,579 |
| Eli Lilly | 21 | $303,765 |
| GSK | 41 | $190,841 |
| Gilead | 30 | $64,882 |
| Kadmon Corporation LLC | 6 | $52,391 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $22,479 |
| Akebia Therapeutics Inc | 12 | $21,090 |
| Boehringer Ingelheim International GmbH | 4 | $6,150 |
| Biogen | 1 | $3,987 |
| Vifor Pharma, Inc. | 6 | $1,970 |
| Astrazeneca UK Limited | 6 | $638 |
| Mallinckrodt Hospital Products Inc. | 9 | $338 |
| Calliditas Therapeutics US Inc. | 5 | $172 |
| Ardelyx, Inc. | 2 | $144 |
| Mallinckrodt Enterprises LLC | 1 | $122 |
| Johnson & Johnson | 1 | $115 |
| Bayer | 1 | $109 |
| Bard Peripheral Vascular, Inc. | 1 | $108 |
| Amgen | 5 | $106 |
| Travere Therapeutics, Inc. | 3 | $94 |
| Otsuka America Pharmaceutical, Inc. | 3 | $73 |
| Novo Nordisk | 3 | $63 |
| Fresenius USA Marketing, Inc. | 3 | $59 |
| OPKO Pharmaceuticals, LLC | 2 | $44 |
| Boston Scientific | 1 | $42 |
| Lilly USA, LLC | 2 | $35 |
| Aurinia Pharma U.S., Inc. | 1 | $32 |
| Kyowa Kirin, Inc. | 1 | $29 |
| Boehringer Ingelheim | 2 | $27 |
| Scpharmaceuticals Inc. | 1 | $26 |
| Renalytix AI, Inc. | 1 | $23 |
| Novartis | 1 | $22 |
How this compares
$1,085,556 in reported general payments places this provider in the 95th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Port Charlotte
- Thomas MarburyOrlando$41.1M
- Julio VijilHollywood$16.1M
- Steven ZeigHollywood$14.3M
- Oscar GalvezMiami$14.2M
- Jesus NavarroTampa$13.3M
- Arvind MadanOrlando$9.7M
- David HalpertAtlantis$4.2M
- Wayne KotzkerFort Lauderdale$3.4M
- Edouard MartinLauderdale Lakes$2.7M
- Jorge PosadaCoral Gables$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.